Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Nørgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, Poulsen HS, Moses HL (1999) Clin Cancer Res 5: 35-42 Mob-1, a Ras target gene, is overexpressed in colorectal cancer. Zhang R, Zhang H, Zhu W, Pardee AB, Coffey RJ, Liang P (1997) Oncogene 14: 1607-10 Novel variants at KCTD10, MVK, and MMAB genes interact with dietary carbohydrates to modulate HDL-cholesterol concentrations in the Genetics of Lipid Lowering Drugs and Diet Network Study. Junyent M, Parnell LD, Lai CQ, Lee YC, Smith CE, Arnett DK, Tsai MY, Kabagambe EK, Straka RJ, Province M, An P, Borecki I, Ordovás JM (2009) Am J Clin Nutr 90: 686-94 Rational modification of a candidate cancer drug for use against Chagas disease. Kraus JM, Verlinde CL, Karimi M, Lepesheva GI, Gelb MH, Buckner FS (2009) J Med Chem 52: 1639-47 Structural elucidation of cisoid and transoid cyclization pathways of a sesquiterpene synthase using 2-fluorofarnesyl diphosphates. Noel JP, Dellas N, Faraldos JA, Zhao M, Hess BA, Smentek L, Coates RM, O'Maille PE (2010) ACS Chem Biol 5: 377-92 Crystal structure of albaflavenone monooxygenase containing a moonlighting terpene synthase active site. Zhao B, Lei L, Vassylyev DG, Lin X, Cane DE, Kelly SL, Yuan H, Lamb DC, Waterman MR (2009) J Biol Chem 284: 36711-36719 Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway. Law BK, Nørgaard P, Gnudi L, Kahn BB, Poulson HS, Moses HL (1999) J Biol Chem 274: 4743-8 Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli. Law BK, Norgaard P, Moses HL (2000) J Biol Chem 275: 10796-801 Interaction of the transforming growth factor-beta type I receptor with farnesyl-protein transferase-alpha. Kawabata M, Imamura T, Miyazono K, Engel ME, Moses HL (1995) J Biol Chem 270: 29628-31 Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo. Okadome T, Oeda E, Saitoh M, Ichijo H, Moses HL, Miyazono K, Kawabata M (1996) J Biol Chem 271: 21687-90 Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Buckner FS, Bahia MT, Suryadevara PK, White KL, Shackleford DM, Chennamaneni NK, Hulverson MA, Laydbak JU, Chatelain E, Scandale I, Verlinde CL, Charman SA, Lepesheva GI, Gelb MH (2012) Antimicrob Agents Chemother 56: 4914-21 Farnesyltransferase inhibitor-induced regression of mammary tumors in TGF alpha and TGF alpha/neu transgenic mice correlates with inhibition of map kinase and p70s6 kinase phosphorylation. Nørgaard P, Law BK, Plovisson HS, Moses HL (1999) Ann N Y Acad Sci 886: 265-8 Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta. Du J, Jiang B, Coffey RJ, Barnard J (2004) Mol Cancer Res 2: 233-41 Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Arteaga CL, Khuri F, Krystal G, Sebti S (2002) Semin Oncol 29: 15-26 Investigating conservation of the albaflavenone biosynthetic pathway and CYP170 bifunctionality in streptomycetes. Moody SC, Zhao B, Lei L, Nelson DR, Mullins JG, Waterman MR, Kelly SL, Lamb DC (2012) FEBS J 279: 1640-9 The bis-electrophile diepoxybutane cross-links DNA to human histones but does not result in enhanced mutagenesis in recombinant systems. Loecken EM, Dasari S, Hill S, Tabb DL, Guengerich FP (2009) Chem Res Toxicol 22: 1069-76 A novel homozygous SCO2 mutation, p.G193S, causing fatal infantile cardioencephalomyopathy. Mobley BC, Enns GM, Wong LJ, Vogel H (2009) Clin Neuropathol 28: 143-9
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.